{"prompt": "['Product: MK-3475', '42', 'Protocol/Amendment No.: 604-09', 'Table 4', 'Dose Modification and Toxicity Management Guidelines for Immune-Related AEs Associated With Pembrolizumab', 'General instructions:', '1. Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 weeks.', '2. For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid', 'has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 weeks of last dose or corticosteroids cannot', 'be reduced to 10 mg prednisone or equivalent per day within 12 weeks.', '3. For severe and life-threatening irAEs, IV corticosteroid should be initiated first followed by oral steroid. Other immunosuppressive', 'treatment', 'should', 'be initiated if irAEs cannot be controlled by corticosteroids.', 'Toxicity grade or', 'irAE management with', 'Immune-related', 'conditions', 'Action taken to', 'corticosteroid and/or other', 'AEs', '(CTCAEv4.0)', 'pembrolizumab', 'therapies', 'Monitor and follow-up', 'Pneumonitis', 'Grade 2', 'Withhold', 'Administer', 'corticosteroids', 'Monitor subjects for signs and symptoms of', '(initial dose of 1-2 mg/kg', 'pneumonitis', 'prednisone or equivalent)', 'Evaluate', 'subjects', 'with', 'suspected', 'followed by taper', 'Grade 3 or 4, or', 'pneumonitis with radiographic imaging and', 'Permanently', 'initiate corticosteroid treatment', 'recurrent Grade 2', 'discontinue', 'Add', 'prophylactic', 'antibiotics', 'for', 'opportunistic infections', 'Diarrhea / colitis', 'Grade 2 or 3', 'Withhold', 'Administer', 'corticosteroids', 'Monitor subjects for signs and symptoms of', '(initial dose of 1-2 mg/kg', 'enterocolitis (ie, diarrhea, abdominal pain,', 'prednisone or equivalent)', 'blood or mucus in stool with or without', 'followed by taper', 'fever) and of bowel perforation (ie,', 'peritoneal signs and ileus).', 'Subjects with Grade >2 diarrhea suspecting', 'colitis should consider GI consultation and', 'Grade 4', 'Permanently', 'discontinue', 'performing endoscopy to rule out colitis.', 'Subjects with diarrhea/colitis should be', 'advised to drink liberal quantities of clear', 'fluids. If sufficient oral fluid intake is not', 'feasible, fluid and electrolytes should be', 'substituted via IV infusion.', 'AST / ALT', 'Grade 2', 'Withhold', 'Administer', 'corticosteroids', 'Monitor with liver function tests (consider', 'elevation or', '(initial dose of 0.5-1 mg/kg', 'weekly or more frequently until liver', 'Increased', 'prednisone or equivalent)', 'enzyme value returns to baseline or is stable', 'Bilirubin', 'followed by taper', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '43', 'Protocol/Amendment No.: 604-09', 'Toxicity grade or', 'irAE management with', 'Immune-related', 'conditions', 'Action taken to', 'corticosteroid and/or other', 'AEs', '(CTCAEv4.0)', 'pembrolizumab', 'therapies', 'Monitor and follow-up', 'Grade 3 or 4', 'Permanently', 'Administer corticosteroids', 'discontinue', '(initial dose of 1-2 mg/kg', 'prednisone or equivalent)', 'followed by taper', 'Type 1 diabetes', 'New onset', 'T1DM', 'or', 'Withhold', 'Initiate insulin replacement', 'Monitor subjects for hyperglycemia or other', 'mellitus (T1DM)', 'Grade', '3', 'or', '4', 'therapy for subjects with', 'signs and symptoms of diabetes.', 'or', 'hyperglycemia', 'T1DM', 'Hyperglycemia', 'associated with evidence', 'Administer', 'anti-', 'of \u00df-cell failure', 'hyperglycemic in subjects', 'with hyperglycemia', 'Hypophysitis', 'Grade 2', 'Withhold', 'Administer', 'corticosteroids', 'Monitor for signs and symptoms of', 'and', 'initiate', 'hormonal', 'hypophysitis (including hypopituitarism and', 'replacements as clinically', 'adrenal insufficiency)', 'Grade 3 or 4', 'Withhold', 'or', 'indicated.', 'permanently', 'discontinue\u00b9', 'Hyperthyroidism', 'Grade 2', 'Continue', 'Treat with non-selective beta-', 'Monitor for signs and symptoms of thyroid', 'blockers (eg, propranolol) or', 'disorders.', 'thioamides as appropriate', 'Grade 3 or 4', 'Withhold or', 'Permanently', 'discontinue\u00b9', 'Hypothyroidism', 'Grade 2-4', 'Continue', 'Initiate thyroid replacement', 'Monitor for signs and symptoms of thyroid', 'hormones (eg, levothyroxine', 'disorders.', 'or liothyronine) per standard', 'of care', 'Nephritis and', 'Grade 2', 'Withhold', 'Administer', 'corticosteroids', 'Monitor changes of renal function', 'renal dysfunction', '(prednisone', '1-2 mg/kg or', 'Grade 3 or 4', 'Permanently', 'equivalent) followed by taper.', 'discontinue', 'Myocarditis', 'Grade 1 or 2', 'Withhold', 'Based on severity of AE', 'Ensure adequate evaluation to confirm', 'administer corticosteroids', 'etiology and/or exclude other causes', 'Grade 3 or 4', 'Permanently', 'discontinue', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}